Predictive Value of a SNP Signature & Liquid Biopsy in NCT04423536

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Clinical Trial Details — Status: Recruiting

The purpose of this study is to determine the Predictive value of a SNP signature and liquid biopsy in patients with natural killer T-cell lymphoma.

Recruitment information / eligibility
Status	Recruiting
Enrollment	800
Est. completion date	March 2025
Est. primary completion date	March 2025
Accepts healthy volunteers	No
Gender	All
Age group	18 Years and older
Eligibility	Inclusion Criteria: - biopsy proved Natural Killer T-cell Lymphoma - newly diagnosed patients Exclusion Criteria: - patients with biopsy samples unavailable

Locations
Country	Name	City	State
China	Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,	Guangzhou

Sponsors *(1)*
Lead Sponsor	Collaborator
Sun Yat-sen University

China,

Outcome
Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival		5-years